FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096779319> ?p ?o ?g. }

• W3096779319 abstract "The extracellular ATP/adenosine axis in the tumor microenvironment (TME) has emerged as an important immune-regulatory pathway. Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), otherwise known as CD39, is highly expressed in the TME, both on infiltrating immune cells and tumor cells across a broad set of cancer indications. CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5ʹ-nucleotidase/CD73 to immunosuppressive adenosine. Directly inhibiting the enzymatic function of CD39 via an antibody has the potential to unleash an immune-mediated anti-tumor response via two mechanisms: 1) increasing the availability of immunostimulatory extracellular ATP released by damaged and/or dying cells, and 2) reducing the generation and accumulation of suppressive adenosine within the TME. Tizona Therapeutics has engineered a novel first-in-class fully human anti-CD39 antibody, TTX-030, that directly inhibits CD39 ATPase enzymatic function with sub-nanomolar potency. Further characterization of the mechanism of inhibition by TTX-030 using CD39+ human melanoma cell line SK-MEL-28 revealed an uncompetitive allosteric mechanism (α < 1). The uncompetitive mechanism of action enables TTX-030 to inhibit CD39 at the elevated ATP concentrations reported in the TME. Maximal inhibition of cellular CD39 ATPase velocity was 85%, which compares favorably to results reported for antibody inhibitors to other enzyme targets. The allosteric mechanism of TTX-030 was confirmed via mapping the epitope to a region of CD39 distant from its active site, which suggests possible models for how potent inhibition is achieved. In summary, TTX-030 is a potent allosteric inhibitor of CD39 ATPase activity that is currently being evaluated in clinical trials for cancer therapy." @default.
• W3096779319 created "2020-11-09" @default.
• W3096779319 creator A5008964652 @default.
• W3096779319 creator A5012961044 @default.
• W3096779319 creator A5026884093 @default.
• W3096779319 creator A5029620715 @default.
• W3096779319 creator A5036036045 @default.
• W3096779319 creator A5051092770 @default.
• W3096779319 creator A5052019314 @default.
• W3096779319 creator A5055499202 @default.
• W3096779319 creator A5059120759 @default.
• W3096779319 creator A5070538477 @default.
• W3096779319 creator A5089579825 @default.
• W3096779319 creator A5091640434 @default.
• W3096779319 date "2020-01-01" @default.
• W3096779319 modified "2023-10-11" @default.
• W3096779319 title "Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism" @default.
• W3096779319 cites W1491974553 @default.
• W3096779319 cites W1811799314 @default.
• W3096779319 cites W1834409279 @default.
• W3096779319 cites W1971596340 @default.
• W3096779319 cites W1976147879 @default.
• W3096779319 cites W1980639002 @default.
• W3096779319 cites W1990759477 @default.
• W3096779319 cites W1995321301 @default.
• W3096779319 cites W1998492040 @default.
• W3096779319 cites W2005717890 @default.
• W3096779319 cites W2011833926 @default.
• W3096779319 cites W2024544687 @default.
• W3096779319 cites W2026003140 @default.
• W3096779319 cites W2032608892 @default.
• W3096779319 cites W2037093616 @default.
• W3096779319 cites W2038134454 @default.
• W3096779319 cites W2042565844 @default.
• W3096779319 cites W2042906495 @default.
• W3096779319 cites W2051343837 @default.
• W3096779319 cites W2057073863 @default.
• W3096779319 cites W2059124020 @default.
• W3096779319 cites W2060927696 @default.
• W3096779319 cites W2066812682 @default.
• W3096779319 cites W2068352205 @default.
• W3096779319 cites W2072259475 @default.
• W3096779319 cites W2072356706 @default.
• W3096779319 cites W2083751011 @default.
• W3096779319 cites W2095988220 @default.
• W3096779319 cites W2134122465 @default.
• W3096779319 cites W2138599948 @default.
• W3096779319 cites W2151070736 @default.
• W3096779319 cites W2151579964 @default.
• W3096779319 cites W2153092839 @default.
• W3096779319 cites W2160342295 @default.
• W3096779319 cites W2166563565 @default.
• W3096779319 cites W2167410885 @default.
• W3096779319 cites W2167745909 @default.
• W3096779319 cites W2167795547 @default.
• W3096779319 cites W2253038466 @default.
• W3096779319 cites W2255298612 @default.
• W3096779319 cites W2258180218 @default.
• W3096779319 cites W2270180142 @default.
• W3096779319 cites W2396424530 @default.
• W3096779319 cites W2462605598 @default.
• W3096779319 cites W2474535137 @default.
• W3096779319 cites W2511527198 @default.
• W3096779319 cites W2591053562 @default.
• W3096779319 cites W2591655768 @default.
• W3096779319 cites W2752397049 @default.
• W3096779319 cites W2765132620 @default.
• W3096779319 cites W2787597901 @default.
• W3096779319 cites W2792308221 @default.
• W3096779319 cites W2804816658 @default.
• W3096779319 cites W2805097062 @default.
• W3096779319 cites W2809650769 @default.
• W3096779319 cites W2849303123 @default.
• W3096779319 cites W2883867232 @default.
• W3096779319 cites W2945715301 @default.
• W3096779319 cites W2954470234 @default.
• W3096779319 cites W2981813469 @default.
• W3096779319 cites W2981845485 @default.
• W3096779319 cites W2986950076 @default.
• W3096779319 cites W2987822998 @default.
• W3096779319 cites W2994080338 @default.
• W3096779319 cites W2997893040 @default.
• W3096779319 cites W3004193473 @default.
• W3096779319 cites W3006887831 @default.
• W3096779319 cites W333206344 @default.
• W3096779319 doi "https://doi.org/10.1080/19420862.2020.1838036" @default.
• W3096779319 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7646477" @default.
• W3096779319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33146056" @default.
• W3096779319 hasPublicationYear "2020" @default.
• W3096779319 type Work @default.
• W3096779319 sameAs 3096779319 @default.
• W3096779319 citedByCount "19" @default.
• W3096779319 countsByYear W30967793192021 @default.
• W3096779319 countsByYear W30967793192022 @default.
• W3096779319 countsByYear W30967793192023 @default.
• W3096779319 crossrefType "journal-article" @default.
• W3096779319 hasAuthorship W3096779319A5008964652 @default.
• W3096779319 hasAuthorship W3096779319A5012961044 @default.
• W3096779319 hasAuthorship W3096779319A5026884093 @default.
• W3096779319 hasAuthorship W3096779319A5029620715 @default.

• next